2025年1月20日,康诺亚和诺诚健华联合宣布,两家公司及其双方的合资公司共同与Prolium Bioscience(以下简称Prolium)达成许可合作,授权Prolium开发和商业化CD20×CD3双特异性抗体CM355(ICP-B02)。CM355(ICP-B02)是康诺亚和诺诚健华联合开发的双特异性抗体。目前正在中国开展 I/II 期临床试验,旨在评估CM355(ICP-B02)在复发/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.